| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5946599 | Atherosclerosis | 2014 | 7 Pages |
Abstract
Our data are the first quantitative analysis of serum PCSK9 levels in CKD-HD patients. We show that serum PCSK9 in HD-NS patients is decreased and it retains a positive correlation with LDL-C, suggesting that PCSK9 may remain a significant determinant of LDL-C in CKD-HD subjects. We also show that statin therapy disrupts the correlation between LDL-C and PCSK9 in CKD-HD patients. These data suggest that the regulation of LDL-C by PCSK9 remains intact in CKD-HD patients. PCSK9 may also play a role in the metabolism of triglyceride-rich lipoproteins in CKD-HD patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
H. Abujrad, J. Mayne, M. Ruzicka, M. Cousins, A. Raymond, J. Cheesman, M. Taljaard, A. Sorisky, K. Burns, T.C. Ooi,